Axonics® reports preliminary fourth quarter and fiscal year 2020 revenue

Irvine, calif.--(business wire)--axonics modulation technologies, inc. (nasdaq: axnx), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (snm) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited net revenue for the three months and fiscal year ended december 31, 2020. preliminary unaudited net revenue is expected to be in the range of $34.7 to $34.9 million in the fourth quarter 2020, as c
AXNX Ratings Summary
AXNX Quant Ranking